Literature DB >> 6772450

Absorption rate and bioavailability of valproic acid and its sodium from rectal dosage forms.

F Moolenaar, W J Greving, T Huizinga.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6772450     DOI: 10.1007/bf00625806

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  11 in total

1.  [Does medication by rectal route avoid the hepatic barrier?].

Authors:  A QUEVAUVILLER; Y JUND
Journal:  Ann Pharm Fr       Date:  1951 Sep-Oct

2.  Pharmacokinetics and bioavailability of sodium valproate.

Authors:  U Klotz; K H Antonin
Journal:  Clin Pharmacol Ther       Date:  1977-06       Impact factor: 6.875

3.  Determination of lower fatty acids, particularly the anti-epileptic dipropyl-acetic acid, in biological materials by means of micro diffusion and gas chromatography.

Authors:  J W Meijer; L Hessing-Brand
Journal:  Clin Chim Acta       Date:  1973-01-24       Impact factor: 3.786

4.  Concentration of dipropylacetate in plasma.

Authors:  P Loiseau; A Brachet; P Henry
Journal:  Epilepsia       Date:  1975-11       Impact factor: 5.864

Review 5.  Sodium di-N-propylacetate (DPA) in the treatment of epilepsy. A review.

Authors:  D Simon; J K Penry
Journal:  Epilepsia       Date:  1975-11       Impact factor: 5.864

6.  Rectal administration of sodium valproate in status epilepticus.

Authors:  F J Vajda; G W Mihaly; J L Miles; G A Donnan; P F Bladin
Journal:  Neurology       Date:  1978-09       Impact factor: 9.910

7.  Steady-state kinetics of valproic acid in epileptic patients.

Authors:  J Bruni; B J Wilder; L J Willmore; R J Perchalski; H J Villarreal
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

8.  Pharmacokinetics of di-n-propylacetate in epileptic patients.

Authors:  F Schobben; E van der Kleijn; F J Gabreëls
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

Review 9.  Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy.

Authors:  R M Pinder; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-02       Impact factor: 9.546

10.  Disposition of valproic acid in man.

Authors:  R Gugler; A Schell; M Eichelbaum; W Fröscher; H U Schulz
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953

View more
  7 in total

Review 1.  Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions.

Authors:  E J van Hoogdalem; A G de Boer; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

Review 2.  Perioperative substitution of anti-epileptic drugs.

Authors:  Wilma S W Wichards; Alfred F A M Schobben; Frans S S Leijten
Journal:  J Neurol       Date:  2013-09-01       Impact factor: 4.849

3.  Bioavailability of sodium valproate suppositories during repeated administration at steady state in epileptic children.

Authors:  J Issakainen; B F Bourgeois
Journal:  Eur J Pediatr       Date:  1987-07       Impact factor: 3.183

4.  Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension.

Authors:  Pamela L Clemens; James C Cloyd; Robert L Kriel; Rory P Remmel
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 5.  Rectal drug administration: clinical pharmacokinetic considerations.

Authors:  A G de Boer; F Moolenaar; L G de Leede; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

6.  Rectal administration of sodium valproate in children.

Authors:  E Scanabissi; D Dal Pozzo; E Franzoni; C Galloni; G Mengoli; R Calivà
Journal:  Ital J Neurol Sci       Date:  1984-06

Review 7.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.